Back to Agenda
Innovation Gridlock: When Misaligned Policies Threaten Progress for Patients
Session Chair(s)
Alexis Reisin Miller, JD
Head, Global Regulatory Policy
Merck & Co., Inc., United States
Examines how fragmented policies, trade barriers, pricing pressures, and other restrictions create innovation gridlock—blocking or stalling R&D, delaying clinical trials, disrupting supply, and threatening patient access to critical therapies.
Learning Objective : Identify key policy and regulatory misalignments contributing to innovation gridlock in biopharma; Assess the global impact of these barriers on patient access to transformative therapies. and prioritize action based on criticality; Explore opportunities and actionable policy levers to realign systems and accelerate innovation for patients.
Have an account?